Information Provided By:
Fly News Breaks for February 27, 2020
Feb 27, 2020 | 14:31 EDT
Piper Sandler analyst Danielle Brill said she came away from her talks with Zogenix management after the FDA requested more data and extended Fintepla's PDUFA date feeling confident that the drug will be approved and she recommends buying the shares amid today's weakness. The data requested is not related to safety, the request was made very recently and the FDA is likely "buying themselves more time," said Brill, who views the extension as "actually a good sign for approval." She keeps an Overweight rating on Zogenix shares.
News For ZGNX From the Last 2 Days
There are no results for your query ZGNX